story of the week
Safety, Efficacy, and Determinants of Response of Allogeneic CD19-Specific CAR NK Cells in CD19+ B-Cell Tumors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Nature Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial
Nat. Med. 2024 Jan 18;[EPub Ahead of Print], D Marin, Y Li, R Basar, H Rafei, M Daher, J Dou, V Mohanty, M Dede, Y Nieto, N Uprety, S Acharya, E Liu, J Wilson, P Banerjee, HA Macapinlac, C Ganesh, PF Thall, R Bassett, M Ammari, S Rao, K Cao, M Shanley, M Kaplan, C Hosing, P Kebriaei, LJ Nastoupil, CR Flowers, SM Moseley, P Lin, S Ang, UR Popat, MH Qazilbash, RE Champlin, K Chen, EJ Shpall, K RezvaniFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.